금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Iran’s Pezeshkian says no negotiation on ballistic missiles
Iran’s President Masoud Pezeshkian said that Tehran’s ballistic missile program will not be included...
Euro weakens below 1.1400 as Fed hike bets lift US Dollar
The EUR/USD pair trades on a negative note near 1.1380 during the early Asian trading hours on Wedne...
BoJ Summary of Opinions: Member says suitable to keep hiking as conditions remain accommodative
The Bank of Japan (BoJ) published the Summary of Opinions from the June monetary policy meeting, wit...
Warsh, SpaceX & Iran Rule Last Week: 5 Leveraged ETF Winners
Warsh's Fed debut, SpaceX's AI deal and Iran headlines fueled a risk-on rally. These 5 leveraged ETFs soared as much as 94% last week.
British Pound: Political change and flows – BNY
BNY’s Geoff Yu highlights that Sir Keir Starmer’s resignation and the likely appointment of Andy Burnham as Prime Minister are largely priced into U.K. assets.
A 40% market crash is lurking in the IPO pipeline. SpaceX and OpenAI could trigger it.
Prior records for U.S. equity issuance came in 1929 and 2000 — and we all know what happened next.
Rayonier Advanced Materials names new CEO amid strategic review; shares up
Former Federal Reserve chairman Alan Greenspan dies at 100
The legendary central banker led the Fed for nearly two decades.
US Equity Futures Largely Flat Pre-Bell As US-Iran Talks Start in Switzerland
US equity futures were mostly unchanged flat pre-bell Monday as traders considered the latest develo
Which Bond ETF Is the Better Buy: iShares' MUB or Vanguard's VGIT?
Compare tax advantages, risk profiles, and portfolio strategies as these two bond ETFs take different paths to income and stability.
Fervo Energy to partner with Nvidia, PNNL on geothermal digital twin
Big Tech is splitting into two artificial-intelligence camps. Here is the better bet.
Why tech giants such as Alphabet and Microsoft are the safer choice in the AI race.
AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion
Apogee Therapeutics is developing a promising atopic dermatitis drug.